newsfilter
← Latest News
GlobeNewswire·

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months